Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 3
Where in Egypt
- Faculty of Medicine Cairo UniversityCairo, EgyptContact: Riham M Mohamed, MD, MSc., PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cairo University
- Trial code
- NCT07904910
- Record updated
- 29 October 2026
- Original description
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment.Read full original descriptionShow less
The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment.
The main questions it aims to answer is:
* Does crisaborole 2% ointment work effectively in stable localized facial vitiligo in pediatrics and adults? * is crisaborole 2% ointment well tolerated in stable localized facial vitiligo in pediatrics and adults? * Is crisaborole 2% ointment comparable to tacrolimus 0.1% ointment in terms of efficacy and safety in stable localized facial vitiligo in pediatrics and adults?
Researchers will compare crisaborole 2% ointment to tacrolimus 0.1% ointment to see if crisaborole works as effective and is as well-tolerated.
Participants will:
* apply topical crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily for 6 months (or until complete repigmentation, whichever earlier) to patches of stable facial vitiligo. * Visit the clinic twice every week for Excimer light sessions, checkups, and photography. * Keep a diary of their symptoms.
Inclusion: Age ≥ 6 years old; Both male and female patients; Localized facial vitiligo involving less than 50% of the facial surface area; Stable vitiligo defined by fulfillment of both of the following criteria simultaneously at screening:; Vitiligo Disease Activity (VIDA) score ≤ 0; Vitiligo Signs of Activity Score (VSAS) = 0; Ability and willingness to comply with treatment and follow-up visits.
Exclusion: Any topical treatment (such as topical steroids, calcineurin inhibitors, vitamin D analogs, JAK inhibitors, PDE4i) requires a washout period of 2 weeks before screening visit and through the final safety follow-up visit; Ultraviolet light exposure, including UVB/UVA/PUVA delivered by booth/excimer laser, or tanning bed exposure, requires a washout period of 8 weeks before screening and through the final safety follow-up visit; History of transplantation procedure for vitiligo within the past 6 months; History of hypersensitivity to the study medication; History of any skin bleaching treatment for vitiligo or other dermatoses at any point; Any contraindication to excimer light therapy e.g., history of skin cancer, photosensitivity disorders; Current history of systemic therapy or phototherapy; Patients younger than 6 years; Segmental vitiligo; Vitiligo universalis; Pregnancy \& breastfeeding.